Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 518 across all filing types
Latest filing 2025-05-15 Legal Proceedings Report
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Aktualizacja informacji dotyczącej współpracy z BIT - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document is a formal report from Scope Fluidics S.A. detailing a significant event: its subsidiary received notice that a key supplier (BIT Analytical Instruments GmBH) filed for preliminary insolvency proceedings. The text discusses the impact assessment on ongoing projects (BACTEROMIC) and future plans, including seeking alternative suppliers. This type of disclosure regarding a major operational risk, legal/contractual issue, or significant external event that impacts business continuity or strategic goals is typically classified as a Legal Proceeding Report (LTR) or a general Regulatory Filing (RNS). Since it specifically concerns a legal/insolvency event impacting operations, LTR is a strong candidate. However, given the context of Polish regulatory filings (often using 'raport bieżący' for material non-public information), and the nature being an update on a critical supplier's legal status, it fits best under the general category for significant, non-standard operational/legal updates that aren't standard financial reports (10-K, IR, ER). LTR covers significant lawsuits and regulatory actions. While insolvency is a legal matter, RNS is often used for material, non-financial operational updates that don't fit elsewhere. Given the detailed nature of the event disclosure and the ongoing monitoring mentioned ('Scope będzie informowała na bieżąco'), it is a material regulatory disclosure. Since LTR specifically mentions 'significant lawsuits, regulatory actions, or legal matters,' and insolvency proceedings fall under legal matters, LTR is the most precise fit over the general RNS, although RNS is a possibility if LTR is too narrow. I will select LTR as it directly addresses a legal/insolvency event impacting operations.
2025-05-15 Polish
Zmiana terminu publikacji raportu za I kwartał 2025 r. - Content (PL)
Report Publication Announcement Classification · 100% confidence The document text is very short (387 characters) and explicitly states that the Management Board is informing about the publication schedule of periodic reports, specifically announcing a change in the release date for the consolidated report for Q1 2025. This is an announcement about the timing of a report release, not the report itself. This aligns perfectly with the definition of 'Report Publication Announcement' (RPA), which covers announcements regarding the timing or release of company reports.
2025-05-15 Polish
Złożenie "pre-submission" w ramach procesu zmierzającego do certyfikacji systemu BACTEROMIC w ramach procedury FDA - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is short (1062 characters) and discusses a specific regulatory step taken by a subsidiary: submitting a 'pre-submission' request to the FDA for a medical device system (BACTEROMIC). This action relates to obtaining regulatory feedback for the US market entry. This is not a full financial report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). It is a specific update concerning legal/regulatory strategy regarding market approval. Among the provided codes, 'Legal Proceedings Report' (LTR) is the closest fit for significant updates on regulatory actions or legal matters involving the company's path to market, although 'Regulatory Filings' (RNS) is a strong secondary candidate if LTR is too focused on litigation. Given the context of FDA submission strategy, which is a critical regulatory hurdle, LTR seems more appropriate than the general fallback RNS, as it details a specific regulatory engagement process that could lead to future legal/approval hurdles. However, since this is an announcement about a procedural step (pre-submission) rather than a formal lawsuit or final approval/denial, the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory announcements, is often used for such specific, non-standard regulatory updates that don't fit the other defined categories like ER, 10-K, or DIV. Given the nature of the update (FDA pre-submission feedback request), RNS is the most appropriate general regulatory announcement category.
2025-05-09 Polish
Informacja o przyznaniu patentu spółce Bacteromic przez Urząd Patentów i Znaków Towarowych Stanów Zjednoczonych
Regulatory Filings Classification · 100% confidence The document text is a short announcement (1178 characters) written in Polish. It details the granting of a US patent (US 12290807 B2) to a subsidiary (Bacteromic) for a specific technology related to microfluidic chips for microbiological testing. This type of announcement, concerning intellectual property rights, specifically patent grants, does not fit neatly into the primary financial reporting categories (10-K, IR, ER, etc.). Since it is a specific legal/IP update and not a general regulatory filing fallback (RNS), the closest fit among the provided options is 'Legal Proceedings Report' (LTR) if interpreted broadly to include IP protection/grants, or 'Regulatory Filings' (RNS) as a catch-all for specific, non-standard announcements. Given the context of patent grants being a form of legal protection/update, LTR is a possibility, but RNS is the designated fallback for miscellaneous regulatory/legal announcements that don't fit elsewhere. Since this is a specific announcement about a granted patent, which is a form of legal asset protection, and not a general regulatory filing, I will classify it as a specific legal/IP update. However, looking closely at the definitions, there is no specific 'Patent Grant' code. Therefore, it falls under the general category for specific legal matters or the fallback. Given the nature of patent grants being a significant legal/IP event, and lacking a dedicated IP code, I will use the fallback 'RNS' as it is a specific, non-standard announcement not covered by the other codes, or consider if it fits LTR (Legal Proceedings Report). LTR usually implies litigation or regulatory action *against* the company. Since this is a positive IP grant, RNS (Regulatory Filings/Miscellaneous Announcement) is the most appropriate fallback.
2025-05-07 Polish
Informacja o przyznaniu patentu spółce Bacteromic przez Urząd Patentów i Znaków Towarowych Stanów Zjednoczonych - Content (PL)
Regulatory Filings Classification · 100% confidence The document text announces that the United States Patent and Trademark Office has granted a patent to a subsidiary of the company. This is a specific announcement regarding intellectual property rights and commercial exclusivity in the US market. This type of announcement, detailing the granting of a patent and its implications, does not fit neatly into the standard financial reporting categories (10-K, ER, IR, etc.). It is a specific corporate event announcement related to assets/technology. Since there is no specific category for 'Patent Grant Announcement', and it is not a general regulatory filing (RNS) or a legal proceeding (LTR), it is best classified as a miscellaneous corporate announcement. Given the options, 'Regulatory Filings' (RNS) serves as the best general fallback for specific, non-standard corporate news that isn't covered elsewhere, although 'LTR' (Legal Proceedings Report) might sometimes cover IP disputes, this is a grant announcement, not a dispute. However, considering the nature of the announcement (a positive corporate development regarding IP), and the lack of a better fit, RNS is the most appropriate general category for non-standard corporate news.
2025-05-06 Polish
Informacja o przyznaniu patentu europejskiego spółce Bacteromic - Content (PL)
Regulatory Filings Classification · 100% confidence The document text is very short (1073 characters) and announces that the European Patent Office has granted a patent to a subsidiary ('Bacteromic') for a method involving artificial intelligence. This is a specific announcement regarding intellectual property (a patent grant). While 'IP' (Investor Presentation) or 'LTR' (Legal Proceedings Report) might seem tangentially related, the most precise category for an announcement concerning the granting or status of a patent is often categorized under general regulatory or legal updates. Since there is no specific category for 'Patent Grant Announcement', and it is not a full financial report, management change, or standard earnings release, it falls best under the general 'Regulatory Filings' (RNS) as a significant, non-financial, regulatory/legal event announcement, or potentially 'IP' if interpreted broadly as intellectual property news. Given the nature of patent grants being official regulatory actions, RNS is the most appropriate fallback for specific legal/IP news that doesn't fit LTR (which usually implies litigation). However, since the content is purely about securing intellectual property rights, and 'IP' is defined as 'Investor Presentation', I must re-evaluate. The content is a specific legal/regulatory achievement. Given the options, and recognizing this is a specific legal/regulatory event announcement, 'LTR' (Legal Proceedings Report) is often used broadly for significant legal/regulatory milestones, even if it's positive like a patent grant, or 'RNS' as a catch-all. Since it is a formal announcement of a regulatory decision (patent grant), and not a presentation (IP), RNS is the safest general regulatory filing category.
2025-04-28 Polish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.